| Literature DB >> 35162844 |
Masatoshi Nakamura1,2, Kazuki Kasahara1, Riku Yoshida2, Kaoru Yahata2, Shigeru Sato2, Yuta Murakami1, Kodai Aizawa1, Andreas Konrad3.
Abstract
Previous research has shown that vibration foam rolling (VFR) on damaged muscle can result in improvements in muscle soreness and range of motion (ROM). Furthermore, static compression via VFR (i.e., VFR without rolling) can increase the ROM and decrease the muscle stiffness of non-damaged muscle. Therefore, it is likely that static compression via VFR on eccentrically damaged muscle can mitigate muscle soreness and the decrease in ROM, and the decrease in muscle strength. The purpose of this study was to investigate the acute effects of a 90 s bout of VFR applied as a static compression on an eccentrically damaged quadriceps muscle, measuring ROM, muscle soreness, muscle strength, and jump performance. This study was a single-arm repeated measure design. Study participants were sedentary healthy male volunteers (n = 14, 20.4 ± 0.8 years) who had not performed habitual exercise activities or any regular resistance training for at least 6 months before the experiment. All participants performed a bout of eccentric exercise of the knee extensors with the dominant leg and then received a 90 s bout of static compression via VFR of the quadriceps 48 h after the eccentric exercise. The knee flexion ROM, muscle soreness at palpation, and countermovement jump height were measured before the eccentric exercise (baseline), before (pre-intervention) and after the VFR intervention (post-intervention), and 48 h after the eccentric exercise. The results showed that the static compression via VFR significantly (p < 0.05) improved the knee flexion ROM (6.5 ± 4.8%, d = 0.76), muscle soreness at palpation (-10.7 ± 8.6 mm, d = -0.68), and countermovement jump height (15.6 ± 16.0%, d = 0.49). Therefore, it can be concluded that static compression via VFR can improve muscle soreness and function.Entities:
Keywords: countermovement jump height; muscle soreness; muscle strength; pain pressure threshold; range of motion
Mesh:
Year: 2022 PMID: 35162844 PMCID: PMC8834946 DOI: 10.3390/ijerph19031823
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Experimental flow chart.
Changes (mean ± SD) in knee flexion ROM, maximal voluntary isometric contraction (MVC-ISO) torque of the knee extensors, maximal voluntary concentric contraction (MVC-CON) torque at 60°/s, and countermovement jump (CMJ) height, before the maximal eccentric contraction task (baseline), and pre- and post-static compression via VFR. The one-way repeated measure ANOVA results (p-value, F-value, and partial η2 [ηp2]) are shown in the bottom row.
| Knee Flexion ROM | MVC-ISO Torque | MVC-CON Torque | CMJ Height | |
|---|---|---|---|---|
| Baseline | 135.5 ± 8.1 | 157.8 ± 32.1 | 168.1 ± 36.7 | 18.4 ± 3.2 |
| Pre-intervention | 118.2 ± 10.2 * | 101.9 ± 34.8 * | 103.7 ± 41.3 * | 13.4 ± 3.8 * |
| Post-intervention | 125.6 ± 9.2 *, # | 106.6 ± 31.7 * | 112.5 ± 42.7 *, # | 15.0 ± 3.0 *, # |
| ANOVA results |
*: A significant (p < 0.05) difference from the baseline value. #: A significant (p < 0.05) difference from the pre-intervention value.
Changes (mean ± SD) in pain pressure threshold (PPT), tissue hardness, muscle soreness at maximal voluntary isometric contraction (MVC-ISO), maximal voluntary concentric contraction (MVC-CON), stretching, and palpation, before the maximal eccentric contraction task (baseline), and pre- and post-static compression via VFR. The one-way repeated measure ANOVA results (p-value, F-value, and partial η2 [ηp2]) are shown in the bottom row.
| PPT | Tissue Hardness | Muscle Soreness | Muscle Soreness | Muscle Soreness | Muscle Soreness | |
|---|---|---|---|---|---|---|
| Baseline | 2.2 ± 0.8 | 18.2 ± 3.6 | 7.7 ± 6.1 | 7.0 ± 7.7 | 2.1 ± 4.6 | 12.9 ± 10.7 |
| Pre-intervention | 0.9 ± 0.5 * | 20.8 ± 2.5 * | 46.3 ± 20.2 * | 49.0 ± 22.9 * | 42.6 ± 21.9 * | 44.3 ± 17.3 * |
| Post-intervention | 2.3 ± 0.7 # | 18.6 ± 3.0 # | 32.3 ± 20.2 *, # | 31.2 ± 20.2 *, # | 30.3 ± 19.4 *, # | 33.6 ± 14.2 *, # |
| ANOVA results |
*: A significant (p < 0.05) difference from the baseline value. #: A significant (p < 0.05) difference from the pre-intervention value.